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OBJECTIVE—-Cell mass declines progressively during the
course of diabetes, and various antidiabetic treatment regimens
have been suggested to modulate -cell mass. However, imaging
methods allowing the monitoring of changes in -cell mass in
vivo have not yet become available. We address whether pancre-
atic -cell area can be assessed by functional test of insulin
secretion in humans.
RESEARCH DESIGN AND METHODS—A total of 33 patients
with chronic pancreatitis (n  17), benign pancreatic adenomas
(n  13), and tumors of the ampulla of Vater (n  3) at various
stages of glucose tolerance were examined with an oral glucose
load before undergoing pancreatic surgery. Indexes of insulin
secretion were calculated and compared with the fractional
-cell area of the pancreas.
RESULTS—-Cell area was related to fasting glucose concen-
trations in an inverse linear fashion (r  0.53, P  0.0014) and
to 120-min postchallenge glycemia in an inverse exponential
fashion (r  0.89). -Cell area was best predicted by a
C-peptide–to–glucose ratio determined 15 min after the glucose
drink (r  0.72, P  0.0001). However, a fasting C-peptide–to–
glucose ratio already yielded a reasonably close correlation (r 
0.63, P  0.0001). Homeostasis model assessment (HOMA) -cell
function was unrelated to -cell area.
CONCLUSIONS—Glucose control is closely related to pancre-
atic -cell area in humans. A C-peptide–to–glucose ratio after
oral glucose ingestion appears to better predict -cell area than
fasting measures, such as the HOMA index. Diabetes 58:
1595–1603, 2009
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lucose homoeostasis is tightly regulated by the
secretion of insulin from pancreatic -cells (1).
Thus, hyperglycemia develops when insulin se-
cretion is insufﬁcient for a given degree of
insulin resistance, and both type 1 and type 2 diabetes
have been associated with a signiﬁcant deﬁcit in -cell
mass (65% in type 2 diabetes, 99% in type 1 diabetes)
(2–4). Therapeutic approaches aiming to preserve or even
restore -cell mass have therefore gained widespread
attention over the past years (5,6), and a number of agents
have been proposed to prompt -cell regeneration and
thus augment -cell mass in vivo (e.g., glucagon-like
peptide [GLP]-1 analogues and dipeptidyl peptidase-4 in-
hibitors) (7,8). However, because the majority of studies
examining the effects of such compounds on -cell mass
have been carried out under in vitro conditions or in
rodent models, it is difﬁcult to directly translate these
results to humans in vivo. Indeed, although in mice and
rats the endocrine pancreas harbors an enormous capacity
for regeneration (9–11), the overall regenerative potential
of -cells in adult humans appears to be substantially
lower (12). In light of these obvious species differences, it
is crucial to examine longitudinal changes in -cell mass in
humans in more detail. Unfortunately, as yet, all imaging
techniques available have failed to determine -cell mass
in vivo with sufﬁcient accuracy and speciﬁcity (13).
Given this technical inability to monitor changes in
-cell mass in humans, functional tests of insulin secretion
may provide a feasible alternative. However, to be useful
for clinical purposes, such a test would need to 1)b e
sufﬁciently practicable to allow for the repeated examina-
tion of large patient numbers and 2) predict -cell mass
with high accuracy.
The oral glucose tolerance test (OGTT) has commonly
been applied to detect disturbances in glucose homoeosta-
sis in patients at risk of or with overt diabetes, and
different indexes of insulin secretion have been derived
from the OGTT (14). An even less complicated assessment
of -cell function may be derived from indexes based on
fasting glucose and insulin measurements, such as the
homeostasis model assessment (HOMA) index (15). How-
ever, because of the lack of accessibility of the human
pancreas for routine biopsy sampling, the accuracy of
these indexes for the prediction of -cell mass has not yet
been determined in humans. This question is of great
clinical relevance for the design and interpretation of
future clinical trials about the natural course of -cell loss
in type 1 and type 2 diabetes, the impact of various
treatments on -cell mass and turnover, and the time
course of -cell loss after pancreas or islet transplantation.
Therefore, we examined patients with an oral glucose load
before they underwent pancreatic surgery. Different mea-
sures of insulin secretion were determined and related to
the fractional -cell area in the pancreatic tissue that was
collected at surgery. By these means, we addressed the
following questions: 1) Does pancreatic -cell area predict
glycemic control in humans? 2) Do established indexes of
-cell function predict pancreatic -cell area in humans?
and 3) Which measure of insulin secretion and glucose
control derived from a prolonged OGTT shows the closest
association with -cell area?
RESEARCH DESIGN AND METHODS
A total of 33 patients undergoing pancreatic surgery for chronic pancreatitis,
benign pancreatic adenomas, or papillary tumors necessitating partial pancre-
atectomy were studied preoperatively with a 240-min oral glucose challenge.
From the
1Department of Medicine I, St. Josef-Hospital, Ruhr-University
Bochum, Germany; the
2Department of Surgery, St. Josef-Hospital, Ruhr-
University Bochum, Germany; and the
3Department of Pathology, Ruhr-
University Bochum, Germany.
Corresponding author: Juris J. Meier, juris.meier@ruhr-uni-bochum.de.
Received 25 November 2008 and accepted 5 March 2009.
DOI: 10.2337/db08-1611
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
DIABETES, VOL. 58, JULY 2009 1595Different measures of glucose control and insulin secretion were determined
and compared with the fractional -cell area of the partially resected pancreas
to establish potential predictors of -cell area in humans. The study protocol
was approved by the ethics committee of the Ruhr-University Bochum
(registration no. 2528). All patients provided written informed consent before
study enrollment.
Patients. We included 33 patients (17 male, 16 female) undergoing pancreatic
resections in the Department of Surgery, St. Josef-Hospital, Ruhr-University
Bochum, between the years 2004 and 2007. Of these patients, 17 had been
diagnosed with chronic pancreatitis, 13 underwent surgery for the removal of
benign pancreatic adenomas, and 3 underwent partial pancreatectomy be-
cause of tumors of the ampulla of Vater. The clinical diagnoses of chronic
pancreatitis, pancreatic carcinoma, pancreatic adenoma, or ampullary cancer
were conﬁrmed by an independent pathologist in all cases. In patients with
chronic pancreatitis, surgery was performed if conservative treatment ap-
proaches had failed to provide sufﬁcient analgesia. In 9 patients distal
pancreatectomies (pancreas tail resection) were performed, whereas 24
patients were treated with a proximal pancreatectomy (pancreas head resec-
tion). The latter group comprised 17 patients undergoing pancreaticoduode-
nectomy with pylorus preservation, 4 patients undergoing duodenum-
preserving pancreatic head resections according to Beger, and 3 patients
undergoing classic partial pancreaticoduodenectomy (Whipple’s operation).
Diabetes was previously known in six patients (treated with insulin in four
patients, glimepiride in one, and diet in one), whereas the other patients had
no history of known diabetes. Renal function was normal (serum creatinine
1.2 mg/dl) in 27 patients, whereas 6 patients had mild impairments in renal
function (serum creatinine 1.2–2.0 mg/dl). None of the patients had a severe
impairment in renal function. There also were no differences in the concen-
trations of creatinine and urea between the groups with normal glucose
tolerance (NGT), impaired glucose tolerance (IGT)/impaired fasting glucose
(IFG), and diabetes (Table 1).
Experimental procedures. The experiments were performed in the morning
after an overnight fast with subjects in a supine position throughout the
experiments. All other concomitant medications had been withdrawn since
the evening of the preceding day. All antidiabetic treatment was withheld at
least 24 h before the experiments. In insulin-treated patients, the last injection
of short-acting insulin was performed on the evening before the tests, whereas
all long-acting insulins were withheld for at least 24 h to avoid carryover
effects.
No restrictions were made regarding the intake of water until the morning
of the experiments. Both ear lobes were made hyperemic using Finalgon (4
mg/g Nonivamid, 25 mg/g Nicoboxil). The experiments were started by the
ingestion of the oral glucose load (75 g glucose in 300 ml) over 5 min, and
capillary and venous blood samples were drawn at t  5, 0, 15, 30, 60, 90,
120, 150, 180, 210, and 240 min. Capillary blood samples (100 l) were added
to NaF (Microvette CB 300; Sarstedt, Nu ¨mbrecht, Germany) for the immediate
measurement of glucose. Venous blood was drawn into chilled tubes contain-
ing EDTA and aprotinin (20,000 kIU/ml Trasylol, 200 l per 10 ml blood; Bayer,
Leverkusen, Germany) and kept on ice. After centrifugation at 4°C, plasma for
hormone analyses was kept frozen at 28°C.
Measurements. Glucose was measured as previously described (16) using a
glucose oxidase method with a Glucose Analyzer 2 (Beckman Instruments,
Munich). To adjust for the glucose concentration differences between capil-
lary plasma and whole blood, glucose measurements were divided by the
correction factor 1.11 (17).
Insulin was measured as previously described (16), using an insulin
microparticle enzyme immunoassay (IMx Insulin; Abbott Laboratories, Wies-
baden, Germany). Cross-reactivity with proinsulin was 0.005%. The intra-
assay CV was 4%. C-peptide was measured as previously described (16), using
an enzyme-linked immunosorbent assay from Dakop (Cambrigshire, U.K.).
The intra-assay CV was 3.3–5.7%, and the interassay CV was 4.6–5.7%. Human
insulin and C-peptide were used as standards.
Pancreatic tissue processing. Pancreatic resections were ﬁxed in formal-
dehyde and embedded in parafﬁn for subsequent analysis as previously
described (12). Sequential 5-m sections were stained for insulin using a
guinea pig anti-insulin antibody (no. A 0564, lot no. 00001500; Dako) at 1:400
dilution and an Alkaline Phosphatase/RED detection system (REAL Envision
detection system, no. K 5007 and K 5005, lot no. 00025382 and 00025812,
respectively; Dako).
Morphometric analysis. For determination of the fractional -cell areas,
entire pancreatic sections stained for insulin were imaged at 100 magniﬁ-
cation (10 objective) using a Zeiss Axioplan microscope equipped with a
motorized stage. A tile image of the tissue section was generated using the
Mosaix tool of Zeiss Axiovision version 4.5 software. The fractional areas of
the pancreas stained positive for insulin were digitally quantiﬁed using a
color-based threshold using Axiovision software as previously described (12).
Calculations and statistical analysis. The HOMA index for -cell function
was calculated as previously described (15). Insulin-to-glucose ratios and
C-peptide–to–glucose ratios were calculated at all time points before and after
oral glucose ingestion. Subject characteristics are reported as the means 
SD, and results are presented as the means  SE.
To address whether pancreatic -cell area predicts glycemic control, the
fractional -cell area was ﬁrst correlated to the fasting and 120-min postchal-
lenge glucose concentrations and the A1C levels because these parameters
have previously been validated as markers of glucose control. To address
whether pancreatic -cell area can be predicted by established indexes of
-cell function, the following parameters were correlated with -cell area: 1)
the HOMA -cell function index, 2) the fasting insulin-to-glucose ratio, 3) the
fasting C-peptide–to–glucose ratio, 4) the insulin-to-glucose ratio 30 min after
oral glucose ingestion, 5) the C-peptide–to–glucose ratio 30 min after oral
glucose ingestion, 6) the plasma insulin levels 30 min after oral glucose
ingestion, and 7) the plasma C-peptide levels 30 min after oral glucose
TABLE 1
Clinical characteristics of patients with NGT, IGT, and/or IFG and patients with diabetes
Parameter NGT IGT/IFG Diabetes P
Age (years) 55.9  15.9 63.2  13.9 59.0  10.1 0.30
Sex (female/male) 5/3 8/6 3/8 0.22
Clinical diagnoses
Chronic pancreatitis 3 (38) 7 (50) 7 (64) 0.52
Benign adenoma 5 (63) 6 (43) 3 (27) 0.31
Ampullary tumor 0 (0) 1 (7) 1 (9) 0.70
BMI (kg/m
2) 23.6  2.7 23.4  3.2 24.1  4.7 0.69
Waist-to-hip ratio 0.89  0.07 0.89  0.08 0.90  0.06 0.89
RR systolic (mmHg) 116  18 119  35 125  20 0.77
RR diastolic (mmHg) 72  97 3  13 78  10 0.44
A1C (%) 5.7  0.5 5.7  0.5 6.9  1.4* 0.0086
White blood count (n/l) 8,024  1,338 6,717  2,100 6,236  1,845 0.13
Hemoglobin (g/dl) 13.8  1.1 13.2  1.5 13.8  1.5 0.45
Serum amylase (units/l) 41.6  41.6 71.5  74.3 13.8  1.5 0.45
Serum urea (mg/dl) 31.9  4.2 31.2  4.1 31.5  2.9 0.99
Serum creatinine (mg/dl) 0.97  0.11 0.99  0.08 1.0  0.06 0.98
Triglycerides (mg/dl) 100.3  34.9 121.9  49.8 155.2  72.1 0.13
Cholesterol (mg/dl) 209.9  37.0 207.2  45.5 204.5  56.0 0.97
HDL cholesterol (mg/dl) 64.0  22.6 52.4  24.0 44.7  14.5 0.20
LDL cholesterol (mg/dl) 136.2  36.8 143.5  28.0 137.6  39.3 0.87
Data are means  SD, n ,o rn (%). Statistical analysis used ANOVA or 	
2 test. *Signiﬁcantly different vs. control subjects (Duncan’s post hoc
test).
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(15,18–21).
Finally, to identify the strongest predictor of -cell area, the plasma
concentrations of glucose, insulin, and C-peptide as well as the C-peptide–to–
glucose ratios and insulin-to-glucose ratios at all time points during the
prolonged OGTT were correlated with pancreatic -cell area. The parameter
yielding the greatest r value for the correlation with -cell area was consid-
ered to be the best predictor of -cell area. By these means, a total of 50
parameters were tested.
Time course measurements were carried out by unpaired ANOVA, using
Statistica version 5.0 (Statsoft Europe, Hamburg, Germany). By these means,
three different P values were calculated 1) for the determination of overall
differences between the different groups (i.e., NGT, IFG/IGT, and diabetes),
independent of the respective time patterns; 2) for the determination of
differences over the time course, independent of the respective groups; and 3)
for the determination of differences between the groups over the time course.
If a signiﬁcant (P  0.05) interaction between group and time was docu-
mented, values at single time points were compared by one-way ANOVA. All
other parameters were compared by one-way ANOVA. P  0.05 was taken to
indicate signiﬁcant differences. Correlation analyses were carried out using
GraphPad Prism 4 using linear or nonlinear regression functions. Decision
criteria were the respective regression coefﬁcients (r).
RESULTS
Postchallenge excursions of glucose, insulin, and
C-peptide. Oral glucose tolerance was normal in 8 sub-
jects, 2 subjects exhibited impaired fasting glucose alone,
impaired glucose tolerance alone was present in 10 pa-
tients, 2 patients presented with both IFG and IGT, and 11
patients had a diabetic glucose tolerance. Patients with
IGT and IFG were collectively presented as one group for
subsequent analyses.
As expected, postchallenge glucose excursions were
signiﬁcantly higher both in patients with overt diabetes as
well as in patients with IGT/IFG compared with patients
with normal glucose tolerance (P  0.0001) (Fig. 1). This
was accompanied by a marked reduction in both insulin
and C-peptide concentrations after the oral glucose load in
the patients with diabetes (Fig. 1). In contrast, insulin and
C-peptide levels were not signiﬁcantly lower in IGT/IFG
patients compared with NGT subjects.
-Cell area and function. The fractional -cell area of
the pancreas was 1.22  0.14, 1.14  0.13, and 0.43  0.12%
in subjects with NGT, IGT/IFG, and diabetes, respectively
(P  0.0003), corresponding to a 65% -cell deﬁcit in
patients with diabetes (Fig. 2). When the two subjects with
isolated IFG were excluded, the fractional -cell area in
the remaining individuals with IGT was 1.08  0.14%.
-Cell area in the two individuals with isolated IFG (fast-
ing glucose levels 107 and 102 mg/dl, 120-min glucose
levels 106 and 120 min) was 1.48 and 1.45%, respectively.
HOMA -cell function (including all patients examined)
was 81.1  13.0, 37.5  30.0, and 135.1  76.9% for those
with NGT, IGT/IFG, and diabetes, respectively (P  0.36).
There also were no differences in HOMA -cell function
when two outliers (calculated HOMA -cell function 876
and 336%) were excluded (P  0.69) (Fig. 2). The fasting
insulin-to-glucose ratio and the fasting C-peptide–to–glu-
cose ratio were not different between the groups (P  0.76
and P  0.067, respectively) (Fig. 2). In contrast, the
insulin-to-glucose ratio and the C-peptide–to–glucose ratio
30 min after oral glucose ingestion were signiﬁcantly lower
in the patients with diabetes (P  0.033 and P  0.0001,
respectively) (Fig. 2).
Relationship between glucose control and measures
of -cell area and function. There was a signiﬁcant
inverse association between fasting glucose concentra-
tions and the fractional -cell area (r  0.53, P  0.0014)
(Fig. 3). An even closer association than in the fasting state
was obtained when fractional -cell area was expressed in
relation to respective glucose excursions 120 min after an
oral glucose load. However, although the correlation be-
tween -cell area and fasting glucose levels tended to
follow a linear relationship, the association with 120-min
postchallenge glucose concentrations was best described
by an exponential decay function using the following
equation: y  358.6  exp(3.21  x) 
 134.9 (r  0.89)
(Fig. 3). There also was a signiﬁcant exponential relation-
ship between fractional -cell area and A1C levels (r 
0.82) (Fig. 3).
Because C-peptide levels 30 min after oral glucose
ingestion yielded the closest association with postchal-
lenge glucose excursions, this parameter was chosen for
subsequent correlation analyses. There was no signiﬁcant
relationship between fasting glycemia and postchallenge
C-peptide levels (r  0.14, P  0.44) (Fig. 3). In contrast,
there was an inverse exponential relationship between
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FIG. 1. Concentrations of glucose (A), insulin (B), and C-peptide (C)
in eight individuals with NGT (), 14 individuals with IFG and/or IGT
(), and 11 patients with diabetes (‚) after oral ingestion of 75 g
glucose. Data are the means  SE. Statistics were carried out using
repeated-measures ANOVA and denote differences between the exper-
iments (A), differences over time (B), and differences due to the
interaction of experiment and time (AB). *Signiﬁcant (P <0.05)
differences vs. control subjects at individual time points (one-way
ANOVA and Duncan’s post hoc test).
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tion and both the 120-min glucose levels (r  0.82)
(Fig. 3) and A1C concentrations (r 0.53) (Fig. 3). As a
rule, the associations between these parameters of glucose
control and C-peptide excursions were weaker than the
respective associations with fractional -cell area (Fig. 3).
Predictors of -cell area. Fractional -cell area was
compared with different established indexes of -cell
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1598 DIABETES, VOL. 58, JULY 2009function (Fig. 4). There was a signiﬁcant linear relation-
ship between fractional -cell area and the fasting insulin-
to-glucose ratio (r  0.51, P  0.0024), the fasting
C-peptide–to–glucose ratio (r  0.64, P  0.0001), the
insulin-to-glucose ratio 30 min after oral glucose ingestion
(r  0.60, P  0.0002), the C-peptide–to–glucose ratio 30
min after oral glucose ingestion (r  0.68, P  0.0001),
plasma insulin levels 30 min after oral glucose ingestion
(r  0.51, P  0.0027), and C-peptide levels 30 min after
oral glucose ingestion (r  0.57, P  0.0005) (Fig. 4). In
contrast, no signiﬁcant relationship was found between
-cell area and the HOMA index of -cell function (r 
0.03, P  0.88). Also, after excluding two outlier patients,
this association failed to reach statistical signiﬁcance (r 
0.23, P  0.21) (Fig. 5).
To identify the strongest predictors of pancreatic -cell
area, fractional -cell area was correlated with the glu-
cose, insulin, and C-peptide levels as well as with the
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cose ratios obtained before and after oral glucose inges-
tion. Based on these analyses, the plasma glucose levels
measured 120 min after oral glucose ingestion yielded the
closest association with -cell area in an exponential
model (Fig. 6). When a linear regression model was
applied, the plasma glucose concentrations at 60 min after
oral glucose ingestion showed the highest degree of cor-
relation (r  0.80, P  0.0001) (Figs. 6 and 7).
The closest associations between -cell area and indi-
vidual insulin and C-peptide levels were found at t  30
min after the oral glucose load (r  0.51, P  0.0027, and
r  0.57, P  0.0005; respectively) (Fig. 4). An even greater
degree of correlation was obtained when insulin and
C-peptide levels were expressed in relation to the respec-
tive glucose concentrations. By these means, the closest
correlations with fractional -cell area were found for the
C-peptide–to–glucose ratio 15 min after oral glucose in-
gestion (r  0.72, P  0.0001) (Fig. 7) and for the
insulin-to-glucose ratio determined 30 min after the glu-
cose load (r  0.60, P  0.0002) (Fig. 4).
DISCUSSION
The current study was designed to assess the validity of
functional indexes of insulin secretion to predict -cell
area in humans in vivo. Using a combination of oral
glucose tolerance tests carried out before pancreatic sur-
gery and morphometric analyses of the respective pancre-
atic tissue samples, we report that 1) glucose control
deteriorates with declining -cell area in humans, 2) -cell
area is signiﬁcantly related to different functional mea-
sures of insulin secretion, and 3) a C-peptide–to–glucose
ratio determined 15 min after oral glucose ingestion ap-
pears to predict -cell area better than fasting measures of
insulin secretion, such as the HOMA index.
The lack of reliable imaging techniques suitable to
determine -cell mass in vivo has prompted great interest
in the functional assessment of -cell mass (22). Thus, a
number of studies have been performed in different animal
models of diabetes (rats, dogs, baboons, and minipigs)
(23–27). The results of these studies have recently been
elegantly reviewed by Robertson (22). As a rule, signiﬁcant
linear associations between the insulin secretory re-
sponses to arginine or glucagon administration and pan-
creatic -cell mass have been reported in these animal
studies (22). In humans, available information about the
relationship between insulin secretion and -cell mass is
rather sparse, and two different studies have previously
addressed this issue. Teuscher et al. (28) determined
insulin secretory responses to intravenous glucose and
arginine administration in eight subjects undergoing islet
autotransplantation. In this study, all measures of insulin
secretion were closely correlated with the transplanted
islet cell mass. A similar association between the number
of transplanted islet equivalents and insulin levels after
arginine administration was found in patients with type 1
diabetes studied after islet allotransplantation (29). The
current study extends these results by providing for the
ﬁrst time direct evidence for a linear correlation between
intrapancreatic -cell mass and insulin secretion in hu-
mans with and without diabetes in vivo. Of note, none of
the imaging methods available so far has proven to predict
-cell mass with a comparable accuracy as the functional
measures applied herein (13).
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above lend strong support to the use of functional tests for
the assessment of -cell area in humans, it is important to
bear in mind the potential limitations of such an approach.
In fact, even though the overall association between -cell
area and insulin secretion in this study was rather close,
any functional measure of insulin secretion can be con-
founded by a number of factors other than merely the
amount of pancreatic -cells. Along these lines, insulin
secretion can be increased by as much as two- to threefold
under conditions of obesity or insulin resistance (30),
although the actual increase in -cell mass in obese
patients has been estimated to be only 30% (2). Further-
more, the insulin responses to intravenous glucose admin-
istration in patients with type 2 diabetes can be enhanced
acutely by 300% after the infusion of a GLP-1 analogue
over 5 h (31), a time period during which any gain in -cell
mass is far from being realistic. Consistent with this, the
current study has shown that despite the signiﬁcant rela-
tionship between insulin secretion and -cell area, there
was still considerable variability in insulin secretion be-
tween different individuals with a similar extent of -cell
area. In this regard, it is also important to stress that any
association between functional indexes of insulin secre-
tion and -cell area is only valid in the absence of
concomitant antidiabetic treatment.
Moreover, because a large number of functional param-
eters were compared with -cell area, there is a certain
likelihood of signiﬁcant results attributable to multiple
testing. However, the overall number of signiﬁcant asso-
ciations identiﬁed in this study was far in excess of the
expected random probability, and the relationships ob-
served were in good agreement with the primary
hypothesis.
The close inverse relationship between -cell area and
120-min glucose levels during the OGTT is another intrigu-
ing ﬁnding from this study. As much as 80% of the
variations in postchallenge glucose excursions could be
attributed to differences in -cell area. Interestingly, this
relationship was much closer that the respective associa-
tion with fasting glucose concentrations. Taken together,
these results suggest that postprandial glucose control
strictly depends on a sufﬁcient extent of insulin-secreting
-cells, whereas fasting glucose levels may be affected by
a number of additional factors as well. Collectively, these
ﬁndings further emphasize the importance of -cell mass
for the development of diabetes. In this regard, it is
noteworthy that the associations between the different
parameters of glucose control and C-peptide secretion
were even weaker than the respective associations with
-cell area, which may suggest that defects in -cell mass
rather than impairments in -cell function primarily deter-
mine the development of diabetes.
Although -cell area was signiﬁcantly reduced in the
patients with overt hyperglycemia, there was only a very
small reduction in -cell area in the pre-diabetic patients
with IFG and IGT. This ﬁnding seems to be at variance
with previous data by Butler et al. (2) showing an 40%
deﬁcit in -cell area in individuals with IFG. It is therefore
important to bear in mind the differences between these
studies. Thus, Butler et al. examined -cell area in IFG
subjects, whereas the majority of patients in this study
were characterized by IGT. Given the marked differences
in the pathogenesis of IFG and IGT (32), these ﬁndings
suggest that the rise in postchallenge glucose levels is a
rather early phenomenon during the development of dia-
betes, whereas fasting hyperglycemia may be indicative of
a more pronounced -cell loss. Second, in the study by
Butler et al., the diagnostic threshold for IFG was 110
mg/dl (33), whereas the revised ADA criteria with a
glucose threshold of 100 mg/dl were used in this study
(34). By these means, patients with relatively mild alter-
ations in fasting glycemia (i.e., fasting glucose levels
between 100 and 110 mg/dl) were included in the IFG/IGT
group in this study as well, whereas the degree of fasting
hyperglycemia was clearly more pronounced in the previ-
ous study. Finally, it is important to emphasize that all
patients examined in this study underwent pancreatic
surgery for underlying pancreatic disorders (especially
chronic pancreatitis), whereas Butler et al. (2) studied a
group of patients more typical of (pre-) type 2 diabetes. In
line with this, the mean BMI of the patients in the IFG
population studied previously was 37 kg/m
2, whereas the
current group of patients with IFG/IGT had a mean BMI of
23.4 kg/m
2. It is therefore likely that the mechanisms
underlying the -cell destruction in the patients studied
herein were different from those typically found in patients
with type 2 diabetes. Therefore, even though our current
study provides novel information regarding the relation-
ship between -cell area and insulin secretion as well as
glycemic control, the ﬁndings should not be generalized to
the majority of patients with type 2 diabetes.
A number of different functional indexes have been
proposed to estimate -cell function in vivo. Among these,
insulin responses to intravenous glucagon or arginine
administration (with or without glucose potentiation) ap-
pear to provide the most reliable estimates of -cell
function (22). However, broad application of such tests is
clearly limited by their laborious procedures, which pre-
vent the routine examination of larger groups of individu-
als. In contrast, the oral glucose tolerance test can easily
be performed under everyday conditions and is therefore
commonly applied to detect disturbances in glucose con-
trol. The current data showing a close relationship be-
tween both insulin and C-peptide excursions during the
OGTT and the fractional -cell area of the pancreas lend
further support to the broad use of this test and suggest
that postchallenge glucose excursions may not only pre-
dict the risk of developing diabetes, but also allow for
some conclusions regarding the residual -cell area.
Because pancreatic weight cannot readily be measured
at surgery in humans, the fractional -cell area rather than
the total -cell mass has been determined in this study.
Therefore, the actual -cell mass of the patients may still
vary to some extent, depending on the overall size of the
pancreas. However, previous studies including 1,800
patients have demonstrated that pancreatic volume is not
affected by the presence of type 2 diabetes and remains
rather constant during adulthood in humans, suggesting
that the overall impact of this factor on the current results
should be rather minor (35). The close relationship be-
tween postchallenge glycemia and the fractional -cell
area observed in this study is consistent with the postulate
that fractional -cell area rather than pancreatic weight is
the primary determinant of -cell mass and suggests that
in humans, -cell mass may be readily estimated from the
determination of the -cell area in pancreatic tissue
samples.
One important goal of this study was to identify simple
and reliable predictors of -cell area in humans. Judging
from the respective r values alone, the best correlation
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OGTT. However, because this relationship followed an
exponential rather than a linear function, the predictive
value of such postchallenge glucose excursions may be
low, especially in individuals with a relatively normal
-cell area (i.e., 50% of normal). A better estimation of
-cell area may be derived from a C-peptide–to–glucose
ratio at t  15 min after oral glucose ingestion, which in
the current study explained as much as 51% of the varia-
tions in -cell area. However, even a simple C-peptide–to–
glucose ratio under fasting conditions already provides a
reasonable estimate of -cell area. In contrast, the HOMA
-cell function index, which is commonly applied as a
measure of -cell function in clinical studies (36,37), failed
to predict pancreatic -cell area in the setting of this study.
The results of this study may have important conse-
quences for the design and interpretation of future longi-
tudinal studies about the potential effects of different
antidiabetic agents on pancreatic -cell area and the
progression of diabetes. Thus, although there is solid
evidence for a progressive decline in -cell mass and
function with advancing type 2 diabetes from a number of
cross-sectional studies (38,39), the only longitudinal stud-
ies that have examined the course of islet dysfunction in
patients with type 2 diabetes (UKPDS [U.K. Prospective
Diabetes Study] and ADOPT [A Diabetes Outcome Pro-
gression Trial]) have applied the HOMA index as a mea-
sure of -cell function, which, according to the current
results, does not necessarily predict changes in -cell
mass (36,40). In a similar fashion, a number of recent
clinical trials have suggested improvements in -cell func-
tion and presumably -cell mass during treatment with
dipeptidyl peptidase-4 inhibitors and GLP-1 analogues
based on such calculations (37,41). The current study
suggests that although the HOMA index may have some
relevance to estimate the functional integrity of insulin
secretion, it represents an odd surrogate of -cell area in
vivo. Future studies in this area should therefore consider
the use of a C-peptide–to–glucose ratio after oral glucose
ingestion as a functional estimate of -cell area.
In conclusion, the current studies have revealed a close
inverse relationship between postchallenge glycemia and
-cell area in humans in vivo. A C-peptide–to–glucose
ratio after oral glucose ingestion or even in the fasting
state can provide a reasonable estimate of pancreatic
-cell area, whereas the HOMA -cell function index
appears to be less suitable in this regard. Such indexes
may be useful to assess the natural course of -cell loss in
longitudinal studies and to estimate the residual -cell
area in individual patients with diabetes.
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